City Therapeutics, Inc. (CTY)
NASDAQ: CTY · Real-Time Price · USD
22.40
+4.40 (24.44%)
At close: Oct 16, 2026, 4:00 PM EDT
22.15
-0.25 (-1.12%)
After-hours: Oct 16, 2026, 7:58 PM EDT
City Therapeutics Revenue
City Therapeutics had revenue of $3.18M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $14.34M. In the year 2025, City Therapeutics had annual revenue of $13.56M with 388.19% growth.
Revenue (ttm)
$14.34M
Revenue Growth
+388.19%
P/S Ratio
77.71
Revenue / Employee
$191,227
Employees
75
Market Cap
1.11B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.56M | 10.78M | 388.19% |
| Dec 31, 2024 | 2.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
CTY News
- 1 day ago - City Therapeutics opened at $23, IPO priced at $18 per share - TheFly
- 1 day ago - City Therapeutics indicated to open at $22, IPO priced at $18 - TheFly
- 1 day ago - City Therapeutics indicated to open at $20.25, IPO priced at $18 - TheFly
- 1 day ago - City Therapeutics 11.1M share IPO priced at $18.00 - TheFly
- 1 day ago - City Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewsWire
- 8 days ago - City Therapeutics eyes valuation of up to $956.3 million in US IPO amid biotech listing push - Reuters
- 22 days ago - Drug developer City Therapeutics files for US IPO - Reuters
- 22 days ago - City Therapeutics IPO Registration Document (S-1) - SEC